By admin 
The landscape of pediatric oncology is currently witnessing a significant shift toward precision medicine and advanced immunotherapy, as researchers strive to address some of the most recalcitrant forms of childhood cancer. At the forefront of this movement is Dr. John Lee, an associate professor in residence in the Division of Hematology/Oncology at the David Geffen School of Medicine at UCLA. Recently named the recipient of the Acceleration Initiative Award, Dr. Lee is spearheading a research project that seeks to fundamentally alter the prognosis for children diagnosed with metastatic Ewing sarcoma (ES). With a commitment of over $900,000 in funding, this initiative represents a critical investment in a disease where the five-year survival rate for advanced cases has remained stubbornly low, often dipping to 15%. This research aims to move from preclinical validation to clinical application within a condensed three-year timeframe, offering a beacon of hope for families facing a diagnosis that has historically carried a devastating outlook.
The Clinical Challenge of Metastatic Ewing Sarcoma
Ewing sarcoma is a rare and aggressive form of primary bone cancer that primarily affects children, adolescents, and young adults. While advancements in multi-modal therapy—including surgery, high-dose chemotherapy, and radiation—have improved outcomes for patients with localized tumors, the prognosis for those with metastatic or recurrent disease remains dire. In the United States, approximately 200 to 250 new cases are diagnosed annually. For patients whose cancer has spread to the lungs, other bones, or bone marrow at the time of diagnosis, the survival statistics have seen little improvement over the last three decades.
The biological hallmark of Ewing sarcoma is a specific genetic translocation, most commonly involving the EWS gene on chromosome 22 and the FLI1 gene on chromosome 11. This fusion creates an oncogenic protein that drives uncontrolled cell growth. However, targeting this protein directly has proven difficult for traditional drug developers. Furthermore, the tumor microenvironment in Ewing sarcoma is notoriously immunosuppressive, meaning it effectively "hides" from the body’s natural immune defenses, making traditional immunotherapies less effective than they are in adult cancers like melanoma or lung cancer.
Innovation in Immunotherapy: The CAR T-Cell and IL-18 Strategy
Dr. Lee’s research focuses on Chimeric Antigen Receptor (CAR) T-cell therapy, a revolutionary form of treatment where a patient’s own T-cells are harvested, genetically re-engineered to recognize and attack cancer cells, and then infused back into the patient. While CAR T-cell therapy has seen remarkable success in treating "liquid" cancers such as certain types of leukemia and lymphoma, its efficacy in solid tumors like Ewing sarcoma has been limited by the harsh environment of the tumor and the tendency of T-cells to become "exhausted" or inactive before they can eliminate the malignancy.
To overcome these hurdles, Dr. Lee’s team is employing a novel approach: the strategic incorporation of Interleukin-18 (IL-18). IL-18 is a potent pro-inflammatory cytokine that plays a crucial role in the innate and adaptive immune response. By "arming" CAR T-cells with the ability to produce or respond to IL-18, the research team aims to enhance the metabolic fitness and killing capacity of the immune cells. This modification is designed to act as a biological booster, ensuring that the T-cells remain active and aggressive even within the hostile, oxygen-deprived environment of a metastatic tumor.
The preclinical work conducted at UCLA suggests that this dual-action approach—combining the precision of CAR T-cells with the invigorating power of IL-18—could lead to a more durable and effective response against Ewing sarcoma cells. The goal is to create a "living drug" that can seek out microscopic metastatic deposits throughout the body, providing a systemic defense that traditional localized treatments cannot offer.
A Chronology of Progress: From Bench to Bedside
The Acceleration Initiative Award is specifically designed to bridge the "valley of death" in drug development—the gap between laboratory discovery and the start of human clinical trials. The timeline for Dr. Lee’s project is ambitious, reflecting the urgency of the pediatric patient population.
- Phase I: Preclinical Optimization (Current Stage): The team is currently refining the genetic constructs of the IL-18-enhanced CAR T-cells. This involves rigorous testing in laboratory models to ensure maximum efficacy and minimal off-target toxicity.
- Phase II: Investigational New Drug (IND) Preparation: Over the next 18 to 24 months, the research will focus on meeting the stringent safety and manufacturing requirements set by the U.S. Food and Drug Administration (FDA). This includes establishing standardized protocols for the production of the modified cells.
- Phase III: Clinical Trial Initiation (Projected Year 3): The ultimate milestone is the launch of a Phase I clinical trial. This trial will evaluate the safety and preliminary efficacy of the treatment in pediatric patients with metastatic or refractory Ewing sarcoma who have exhausted standard treatment options.
By condensing the traditional decade-long development cycle into just three years, the Acceleration Initiative ensures that scientific breakthroughs do not languish in academic journals but instead reach the hospital bedside where they are most needed.
Supporting Data and the Economic Landscape of Pediatric Research
The necessity for private funding, such as the $900,000 provided for Dr. Lee’s work, is underscored by the current state of federal research spending. While the National Cancer Institute (NCI) provides substantial support for cancer research, only a small fraction of its total budget is dedicated specifically to pediatric cancers. Most pharmaceutical companies focus their research and development budgets on adult cancers due to the larger market size, leaving pediatric orphan diseases like Ewing sarcoma chronically underfunded.
Data from the American Cancer Society indicates that while the overall death rate for childhood cancer has declined by more than 50% since the 1970s, certain subtypes—including metastatic bone sarcomas—have seen the slowest rates of progress. The high cost of developing biologics like CAR T-cells makes philanthropic intervention essential. The investment in Dr. Lee’s project covers not only the scientific labor but also the specialized equipment, viral vectors for genetic engineering, and the administrative costs associated with navigating the regulatory path to a clinical trial.
The Power of Collaboration and Legacy
The funding for this project is the result of a multi-organizational effort, highlighting a growing trend in the non-profit sector where various foundations pool resources to maximize impact. The award is supported by the Rally Foundation for Childhood Cancer Research and three CureSearch Legacy Funds: The Garret Collins Legacy Fund, The Nick Currey Fund, and The Sam Schneider Legacy.
These legacy funds are often established by families who have lost children to cancer, turning their personal grief into a catalyst for scientific advancement. For instance, the family of Sam Schneider has emphasized the importance of early detection and research, noting that Sam’s cancer was already metastatic by the time it was identified—a common and tragic occurrence in Ewing sarcoma patients. Similarly, the family of Nick Currey has advocated for "targeted, less toxic therapies," highlighting the severe long-term side effects often caused by current "blunt force" treatments like high-dose radiation and chemotherapy.
This collaborative funding model ensures that research is not only scientifically rigorous but also deeply aligned with the needs and priorities of the patient community. It creates a direct link between the memory of children lost to the disease and the potential for future cures.
Broader Implications for Pediatric Oncology
The success of Dr. Lee’s research could have implications far beyond Ewing sarcoma. If the IL-18-enhanced CAR T-cell platform proves successful in treating bone cancer, the same technology could potentially be adapted for other pediatric solid tumors, such as osteosarcoma or neuroblastoma. These diseases share similar challenges regarding the immunosuppressive tumor microenvironment and the difficulty of maintaining T-cell potency.
Furthermore, this project serves as a model for how academic institutions like UCLA can work in tandem with philanthropic organizations to bypass traditional bottlenecks in drug development. By focusing on "precision" immunotherapy—treatments tailored to the specific genetic and biological profile of a tumor—oncologists are moving toward a future where "less toxic" is a reality, not just an aspiration.
As Dr. Lee noted, the overarching hope is that by strengthening the patient’s own immune system, the medical community can finally move the needle on survival rates that have remained stagnant for too long. The next three years will be pivotal in determining whether this novel approach will become the new standard of care for children facing the most aggressive forms of Ewing sarcoma. For the children and families currently navigating this diagnosis, the acceleration of this research represents more than just a scientific project; it represents the possibility of a future that was once thought unreachable.
